secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001326110-25-000112
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio Q2 revenue jumps 60% to $26.4M; net loss narrows to $92.6M
----------------------------------------------------------------------

- Q2 product revenue $26.4M, up 60% from Q1 and from $990k in Q2 2024; YTD sales $42.9M.
- Net loss $92.6M ($0.10/share) vs $134.6M in Q2 2024; operating loss narrowed.
- Cash $153.7M at June 30; $80M equity financing closed July 2025 with potential $96M warrant proceeds.
- UK MHRA approved ANKTIVA for BCG-unresponsive NMIBC; FDA refused to file sBLA for papillary-only NMIBC, company re-evaluating.
- ANKTIVA unit volume grew 246% in 1H 2025 vs 2H 2024 since J-code approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/0001326110-25-000112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611025000112/ibrx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001326110-25-000112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer